PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Botulinum toxins - Market size and forecast 2018-2023 • Other therapeutics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Allergan • Eisai • Ipsen Pharma • Merz Pharma • US WorldMeds PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO Exhibit 01: Global CNS therapeutics market Exhibit 02: Segments of global CNS therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Botulinum toxins - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Botulinum toxins - Year-over-year growth 2019-2023 (%) Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Other Therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 23: Market opportunity by product Exhibit 24: Customer landscape Exhibit 25: Market share by geography 2018-2023 (%) Exhibit 26: Geographic comparison Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Americas - Year-over-year growth 2019-2023 (%) Exhibit 29: Top 3 countries in Americas Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in EMEA Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 34: APAC - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in APAC Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Impact of drivers and challenges Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: ALLERGAN - Vendor overview Exhibit 45: ALLERGAN - Business segments Exhibit 46: ALLERGAN - Organizational developments Exhibit 47: ALLERGAN - Geographic focus Exhibit 48: ALLERGAN - Segment focus Exhibit 49: ALLERGAN - Key offerings Exhibit 50: ALLERGAN - Key customers Exhibit 51: Eisai - Vendor overview Exhibit 52: Eisai - Business segments Exhibit 53: Eisai - Organizational developments Exhibit 54: Eisai - Geographic focus Exhibit 55: Eisai - Segment focus Exhibit 56: Eisai - Key offerings Exhibit 57: Eisai - Key customers Exhibit 58: Ipsen Pharma - Vendor overview Exhibit 59: Ipsen Pharma - Business segments Exhibit 60: Ipsen Pharma - Organizational developments Exhibit 61: Ipsen Pharma - Geographic focus Exhibit 62: Ipsen Pharma - Segment focus Exhibit 63: Ipsen Pharma - Key offerings Exhibit 64: Ipsen Pharma - Key customers Exhibit 65: Merz Pharma - Vendor overview Exhibit 66: Merz Pharma - Business segments Exhibit 67: Merz Pharma - Organizational developments Exhibit 68: Merz Pharma - Geographic focus Exhibit 69: Merz Pharma - Segment focus Exhibit 70: Merz Pharma - Key offerings Exhibit 71: Merz Pharma - Key customers Exhibit 72: US WorldMeds - Vendor overview Exhibit 73: US WorldMeds - Organizational developments Exhibit 74: US WorldMeds - Key offerings Exhibit 75: US WorldMeds - Key customers

Allergan Eisai Ipsen Pharma Merz Pharma US WorldMeds